|
|
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2700-2707.
Prepublished online as a Blood First Edition Paper on November 21, 2006; DOI 10.1182/blood-2006-07-025809.
Previous Article | Next Article 
Submitted July 26, 2006
Accepted November 15, 2006
Aberrant NF- B signaling in lymphoma: mechanisms, consequences and
therapeutic implications
Philipp J. Jost and Jurgen Ruland*
III. Medizinsche Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
* Corresponding author; email: jruland{at}lrz.tum.de.
The transcription factor NF- B is a tightly regulated positive mediator of T and B cell development, proliferation and survival. The controlled activity of NF- B is required for the coordination of physiological immune responses. However, constitutive NF- B activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF- B signaling in Hodgkin's disease and a variety of T and B cell non-Hodgkins lymphomas either upstream or downstream of the central I B kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF- B pathway and discusses the mechanisms of NF- B deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin's lymphoma (HL), diffuse large B cell lymphoma (DLBCL), MALT-lymphoma, primary effusion lymphoma (PEL) and adult T cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF- B signaling pathway as an attractive therapeutic target in T and B cell malignancies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. Yan, J. Huang, N. R. Jarbadan, Y. Jiang, and H. Cheng
Sequestration of NF-{kappa}B Signaling Complexes in Lipid Rafts Contributes to Repression of NF-{kappa}B in T Lymphocytes under Hyperthermia Stress
J. Biol. Chem.,
May 2, 2008;
283(18):
12489 - 12500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Ruland
Signaling crosstalk in DLBCL
Blood,
April 1, 2008;
111(7):
3304 - 3304.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Lam, G. Wright, R. E. Davis, G. Lenz, P. Farinha, L. Dang, J. W. Chan, A. Rosenwald, R. D. Gascoyne, and L. M. Staudt
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
Blood,
April 1, 2008;
111(7):
3701 - 3713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. V. Bradley, M. R. Smith, T. S. Hyun, P. C. Lucas, L. Li, D. Antonuk, I. Joshi, F. Jin, and T. S. Ross
Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies
Cancer Res.,
September 15, 2007;
67(18):
8923 - 8931.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |